Oscar Health raises FY 2026 EBITDA guidance by $100M, improves MLR outlook by 50 bps

Oscar Health, Inc.

FY 2026 earnings from operations guidance raised to $600M-$800M from $500M-$700M, up $100M.
FY 2026 medical loss ratio narrowed to 81.0%-82.0% from 81.5%-82.5%, a 50 bps improvement.
Total revenue reaffirmed at $18.7B-$19.0B; SG&A expense ratio reaffirmed at 15.6%-16.1%.
Guidance issued at Sept 16, 2026 Investor Day; webcast archived on IR site for 90 days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.